ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bempedoic acid

Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.

Drug pageBempedoic acid: every studyMany companies study it; this page follows only the 33 they lead. All 43 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 27, 202333 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Esperion Therapeuticsits history only200 open or runningphase 4since Aug 27, 2023Dec 16, 2010none ahead
Daiichi Sankyo61 open or runningphase 4since Apr 6, 2025Apr 6, 2025Jun 1, 2028phase 3 · NCT07474649
Otsukaits history only30 open or runningphase 3since Jan 4, 2023Mar 2, 2021none ahead
Humanis Saglık Anonim Sirketiits history only20 open or runningphase 1since Apr 4, 2025Apr 4, 2025none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since May 29, 2026May 29, 2026Jun 30, 2027phase 3 · NCT07623915
Gan & Lee Pharmaceuticalsits history only10 open or runningphase 3since Jan 13, 2025Jan 13, 2025none ahead

Also a collaborator on its studies: Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 6, 2025First study: phase 4 study in Hyperlipoproteinemia Type IIFirst studyNCT06925100 · 180 enrolled · Taiwan
  2. Sep 11, 20252 phase 1 studies in Healthy SubjectsNCT07182383, NCT07201545
  3. Nov 14, 20252 phase 1 studies in Healthy SubjectsNCT07235189, NCT07268625
  4. Mar 11, 2026Phase 3 study in Coronary Artery DiseaseNCT07474649 · 103 planned · Germany, Italy, Spain

Ahead

  1. Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseNCT07474649

TargetBeta

ACLY →read by rule
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule

Studies

All 6 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07474649Coronary Artery Disease · Germany, Italy, Spain3RecruitingJun 1, 2028103
NCT07268625Healthy Subjects · Portugal1CompletedFeb 24, 202658
NCT07235189Healthy Subjects · Portugal1CompletedJan 28, 202658
NCT07201545Healthy Subjects · Portugal1CompletedDec 10, 202558
NCT07182383Healthy Subjects · Portugal1CompletedNov 24, 202558
NCT06925100Hyperlipoproteinemia Type II · Taiwan4CompletedOct 15, 2025180

How it is read

Names in the registry

  • “ETC-1002”, 10 entries
  • “Bempedoic acid”, 7 entries
  • “180mg of ETC-1002(bempedoic acid)”, 3 entries
  • “bempedoic acid”, 3 entries
  • “Bempedoic Acid Tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.